HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice.

Abstract
Antitumor diabody molecules are noncovalent single-chain Fv dimers that recapitulate the divalent binding properties of native IgG antibodies. Diabodies are capable of substantial accumulation in tumor xenografts expressing relevant antigens in immunodeficient mouse models. With a Mr of approximately 55,000, diabodies are rapidly cleared from the circulation, resulting in tumor-to-blood ratios that significantly exceed those achieved early after the administration of monoclonal antibodies. We have evaluated the therapeutic potential of the beta-emitting isotope yttrium-90 (t1/2, 64 hours) conjugated to the C6.5K-A diabody that specifically targets the HER2/neu human tumor-associated antigen. We have found that a single intravenous dose of 150 microCi (200 microg) 90Y-CHX-A"-C6.5K-A diabody substantially inhibits the growth rates of established MDA-361/DYT2 human breast tumor xenografts in athymic nude mice. In contrast, 300 microCi (300 microg) 90Y-CHX-A"-C6.5K-A diabody resulted in only a minor delay in the growth of SK-OV-3 human ovarian cancer xenografts. The maximum tolerated dose was also dependent on the tumor xenograft model used. These studies indicate that genetically engineered antitumor diabody molecules can be used as effective vehicles for radioimmunotherapy.
AuthorsGregory P Adams, Calvin C Shaller, Ekaterina Dadachova, Heidi H Simmons, Eva M Horak, Abohawariat Tesfaye, Andres J P Klein-Szanto, James D Marks, Martin W Brechbiel, Louis M Weiner
JournalCancer research (Cancer Res) Vol. 64 Issue 17 Pg. 6200-6 (Sep 01 2004) ISSN: 0008-5472 [Print] United States
PMID15342405 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Immunoglobulin Variable Region
  • Immunotoxins
  • Isothiocyanates
  • Yttrium Radioisotopes
  • N-(2-amino-3-(4-isothiocyanatophenyl)propyl)cyclohexane-1,2-diamine-N,N',N',N'',N''-pentaacetic acid
  • Pentetic Acid
  • Receptor, ErbB-2
Topics
  • Animals
  • Breast Neoplasms (diagnostic imaging, immunology, metabolism, radiotherapy)
  • Cell Line, Tumor
  • Female
  • Humans
  • Immunoglobulin Variable Region (administration & dosage, metabolism, pharmacology)
  • Immunotoxins (pharmacokinetics, pharmacology)
  • Isothiocyanates (administration & dosage, pharmacokinetics, pharmacology)
  • Mice
  • Mice, Nude
  • Mice, SCID
  • Ovarian Neoplasms (diagnostic imaging, immunology, metabolism, radiotherapy)
  • Pentetic Acid (administration & dosage, analogs & derivatives, pharmacokinetics, pharmacology)
  • Radioimmunotherapy
  • Radionuclide Imaging
  • Receptor, ErbB-2 (biosynthesis)
  • Tissue Distribution
  • Xenograft Model Antitumor Assays
  • Yttrium Radioisotopes (administration & dosage, pharmacokinetics, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: